Apolipoprotein C3 (ApoCIII) antagonists and methods of their use to remove ApoCIII inhibition of lipoprotein lipase (LPL)
US9783600B2 · kind B2 · utility
0Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 25, 2014 |
| Grant date | Oct 10, 2017 |
| Priority date | — |
| Expiry date | Feb 25, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2521/537
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods of increasing lipoprotein lipase (LPL) activity, by inhibiting apolipoprotein C3 (ApoCIII), which removes the ApoCIII inhibition of LPL, and permits VLDL to be converted to LDL. Also provided are methods for treating or preventing a lipid metabolism disorder, such as type 2 diabetes by use of an ApoCIII antagonist. Also provided are screening methods to identify ApoCIII antagonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.